Cellebrite DI Ltd. CLBT
10.79
(0.58)
(5.10%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 45.0×
Follow CLBT
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
20.46% | 19.10% | 16.44% | 12.42% | |
| 10.43% | 9.61% | 8.65% | 6.60% | ||
ROIC |
0.00% | 87.90% | 48.58% | 36.53% | |
Return on Tangible Assets |
20.41% | 34.29% | 33.61% | 23.50% | |
Average Days of Receivables |
83.42 | 80.55 | 53.48 | 78.62 | |
Free Cash Flow per Share |
0.56 | 0.05 | 0.01 | (0.08) | |
Free Cash Flow |
137.51 | 12.86 | 2.69 | (20.04) | |
Capital Expenditures |
(15.19) | (160.68) | (169.86) | (177.60) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
15.69% | 18.84% | 18.36% | 16.07% | |
Accounts Receivable Turnover |
4.61 | 5.08 | 6.45 | 5.04 | |
Accounts Payable Turnover |
1.08 | 0.93 | 1.04 | 1.01 | |
Inventory Turnover |
7.96 | 9.09 | 9.71 | 9.78 | |
Average Days of Payables |
367.58 | 427.67 | 412.47 | 396.20 | |
Days of Inventory on Hand |
43.18 | 36.92 | 34.30 | 34.94 | |
Tax Rate |
(0.09) | (0.14) | (0.15) | (0.22) | |
Research and Development Expense of Revenue |
24.04% | 23.94% | 24.67% | 25.24% | |
Selling, General and Administrative Expense of Revenue |
46.45% | 46.28% | 46.44% | 46.86% | |
Share Based Compensation of Revenue |
9.25% | 9.44% | 10.17% | 11.07% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.00 | 2.22 | 2.40 | 2.68 | |
Depreciation/Fixed assets |
0.34 | 0.43 | 0.57 | 0.84 | |
Capex/Depreciation |
(2.01) | (16.92) | (12.82) | (8.65) | |
Revenue per Share |
1.87 | 1.97 | 2.01 | 2.08 | |
Operating CF per Share |
0.63 | 0.72 | 0.70 | 0.64 | |
Capex per Share |
(0.06) | (0.66) | (0.69) | (0.72) | |
Capex to Sales |
0.03 | 0.34 | 0.34 | 0.35 | |
Net Profit Margin |
16.74% | 16.47% | 14.48% | 11.43% |
Columns are period end dates